A comprehensive view of RayzeBio Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Bristol Myers Squibb's US$4.1B tender offer to acquire RayzeBio expires, with approximately 86% of RayzeBio's outstanding shares tendered; transaction expected to close on February 26, 2024
Published: February 23, 2024 by Bristol-Myers Squibb Co.
Bristol Myers Squibb moves closer to acquiring RayzeBio after the expiration of antitrust waiting period, paving way for US$4.1B tender offer for the company's common stock
Published: February 12, 2024 by Bristol-Myers Squibb Co.
Bristol Myers to acquire radiopharmaceutical therapeutics biotech RayzeBio for US$4.1B; RayzeBio has a portfolio of actinium-based radiopharmaceuticals to treat solid tumors, small cell lung cancer and other cancers
Published: January 19, 2024 by San Diego Business Journal (CA)
Bristol Myers to acquire radiopharmaceutical therapeutics firm RayzeBio in a deal worth US$4.1B; deal aims to strengthen Bristol Myers' oncology portfolio and support future growth
Published: December 27, 2023 by SeeNews Deals
Bristol Myers adds radiopharmaceutical platform with acquisition of RayzeBio in deal with total equity value of about US$4.1B; deal brings pipeline programs targeting solid tumors, small cell lung cancer, hepatocellular carcinoma and other cancers
Published: December 26, 2023 by Business Wire

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count